Blood Thinners Caused Severe Bleeding in Seriously Ill COVID-19 Patients

Research finds smaller dose of blood thinners is equally effective for blood clots and carries less bleeding risk.

Patients with COVID-19 in the intensive care unit (ICU) prescribed full-dose blood thinners are significantly more likely to experience heavy bleeding than patients prescribed a smaller yet equally effective dose, according to a recent University at Buffalo-led study.

The study compared the safety and effectiveness of blood clot treatment strategies for more than 150 critically ill COVID-19 patients at two hospitals. The results of the study were published in the journal Hospital Pharmacy.

Coronavirus
Coronaviruses infect animals, humans, and birds. Human coronaviruses, such as SARS, MERS, and 2019-nCoV cause respiratory distress and even death. The S protein is the infectious agent of the virus.

‘Nearly one in seven COVID-19 patients in ICU experienced significant bleeding while receiving full-dose blood thinners.’

This study may inform treatment guidelines for blood clots in hospitalized COVID-19 patients, who are at an increased risk for both blood clots and severe bleeding.

“Previous reports have found that 17% of hospitalized COVID-19 patients experience blood clots”, says first author Maya Chilbert, PharmD, clinical assistant professor in the UB School of Pharmacy and Pharmaceutical Sciences.

A wide variety of practice exists when it comes to approaching blood clots in hospitalized patients with COVID-19, and there is little data to suggest improved outcomes using one strategy versus another.

Fluvoxamine: An OCD Drug can Prevent Covid-19 Patients from Hospitalization
Fluvoxamine has been proven among one such drug that could be used to treat COVID-19. Dozens of COVID patients showed no clinical deterioration in their symptoms when treated with a drug, fluvoxamine.

Caution should be used in mechanically ventilated patients with COVID-19 when selecting a regimen to treat blood clots, and the decision to use full-dose blood thinners should be based on a compelling indication rather than lab markers alone.

The study analyzed the outcome of blood clot treatments and the rate of bleeding events for more than 150 patients with COVID-19 who received either of two blood thinner regimens: a full-dose based on patient levels of D-dimer (a protein present in the blood after a blood clot dissolves), and the other a smaller but higher-than-standard dosage.

COVID-19 Vaccination Associated With Menstrual Cycle Length
Menstrual cycle may be delayed in women after being vaccinated for COVID-19.

The average patient age was 58, and all experienced elevated levels of D-dimer, fibrinogen (a protein that helps the body form blood clots), and prothrombin time (a test that measures the time it takes for blood plasma to clot).

Nearly 14% of patients who received full-dose blood thinners experienced a significant bleeding event, compared to only 3% of patients who received a higher-than-standard dosage.

Can Meditation Boost Your Immune System?
Meditation can boost your interferon signaling and help reduce many immune-related conditions such as COVID-19 and multiple sclerosis.

All patients who experienced bleeding events were mechanically ventilated. No difference was reported in the regimens’ effectiveness at treating blood clots.

Further investigation is needed to determine the optimal strategy for treating blood clots and bleeding in hospitalized COVID-19 patients.

Source-Medindia